Beactica’s drug discovery platform delivers promise for brain tumour therapy

06 September 2018

Article in SciTech Europa Quarterly 27, 2018

Beactica's CEO, Dr Per Källblad, explains how the company’s specialist small molecule drug discovery platform is developing a novel therapy for glioblastoma. 

Read full article here.

See all recent coverage

Stay Updated

Sign up for the Beactica newsletter to receive our latest news and updates

This website uses cookies to improve your user experience. By continuing to browse this site, you agree to our use of cookies. More information. Ok!